Latest News for: amyloid-beta

Edit

Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease

Longview News-Journal 02 Apr 2025
Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease ....
Edit

Cognitive flexibility test reveals subtle signs of Alzheimer’s in healthy older adults

PsyPost 02 Apr 2025
It is believed to start long before noticeable symptoms appear, with the accumulation of abnormal proteins like amyloid-beta plaques and tau tangles in areas of the brain such as the medial temporal lobe, which supports memory.
Edit

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial

Hastings Tribune 02 Apr 2025
ABOS), a clinical-stage biopharmaceutical company developing ...
Edit

Low 'Bad' Cholesterol Might Protect Against Dementia, Alzheimer's

Knoxville Daily Sun 02 Apr 2025
Key Takeaways ... More from this section. +3 ... Statins might enhance these effects by reducing brain inflammation and regulating the metabolism of amyloid beta, a brain protein linked to Alzheimer’s, researchers added ... More information ... SOURCES ... ....
Edit

How an unusual medical procedure transmitted Alzheimer’s

Popular Science 01 Apr 2025
Collinge’s group had previously reported that some of the growth hormone batches that four members of the group received had been contaminated with amyloid beta and tau, two proteins that are heavily implicated in the onset of Alzheimer’s disease.
Edit

New blood test checks for Alzheimer’s and assesses progression, study says

The Observer 31 Mar 2025
Plaques of a protein called amyloid beta and the formation of tangles of another protein called tau in the brain are considered hallmarks of Alzheimer’s disease.
Edit

A Protein Ratio Could Predict Alzheimer’s Disease Progression Decades in Advance

The Scientist 31 Mar 2025
In 1906, a 50-year-old woman in Germany died of a mysterious illness ... Scientists now know that the clumps are plaques formed by the protein fragment amyloid-beta (Aβ) and the tangles are abnormal accumulations of the protein tau within neurons ... .
Edit

Early-onset Alzheimer’s: new drug shows promise in slowing the disease

The Conversation 28 Mar 2025
These mutations cause the brain to produce excessive amounts of amyloid beta, a protein that clumps together to form plaques ... Gantenerumab is a monoclonal antibody – a lab-engineered protein designed to attach to amyloid beta in the brain.
Edit

Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of

Hastings Tribune 26 Mar 2025
ABOS), a clinical-stage biopharmaceutical company developing ...
Edit

Dementia Associated With Alzheimer’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism ...

GetNews 26 Mar 2025
NFκB is activated by amyloid beta and tau — two proteins that form toxic clumps that contribute to Alzheimer’s — and by the pro-inflammatory molecules that it stimulates, leading to chronic inflammation.
Edit

Study confirms accuracy of blood test for early Alzheimer's detection in Asian populations

Science Daily 25 Mar 2025
A study has demonstrated the high accuracy of plasma p-tau217 as a blood-based biomarker for detecting abnormal brain beta-amyloid pathology, a hallmark of Alzheimer's disease ... .
Edit

Ask the doctors: Study suggests physical activity slows Alzheimer’s disease

The Spokesman-Review 25 Mar 2025
Dear Doctors ... Dear Reader. You are referring to a study conducted by researchers in Great Britain that appeared in the journal Brain Research ... Alzheimer’s disease is caused by the buildup in the brain of a sticky substance known as beta-amyloid protein.
Edit

Anti-Amyloid Drug Shows Promise In Preventing Alzheimer's

Knoxville Daily Sun 24 Mar 2025
All these drugs were developed based on what’s called the “amyloid hypothesis” of Alzheimer’s, which holds that the disease is caused at least in part by sticky, toxic proteins called amyloid beta that build up in the brain.
Edit

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

Canoe 24 Mar 2025
Rational Design of Alzheimer’s Vaccine to Maximize Selective Targeting of Toxic Amyloid-Beta OligomersAdvertisement 3 ... A large body of evidence indicates that soluble toxic oligomers of amyloid-beta (AβO) are a primary driver of AD.
×